Skip to main content

Table 1 Group mean (minimum-maximum) lameness ratios in untreated control dogs, and in dogs treated with either firocoxib or grapiprant

From: Assessment of the efficacy of firocoxib (Previcox®) and grapiprant (Galliprant®) in an induced model of acute arthritis in dogs

Time (hours post induction) Control Firocoxib Grapriprant
Experiment 1 - treatments administered 2 h prior to induction of arthritis
 1.5 0.49 (0.00–0.89)a 0.90 (0.73–0.99) 0.76 (0.00–1.05)b
 3 0.00 (0.00–0.00)c 0.86 (0.75–0.98)c 0.26 (0.00–0.83)d
 5 0.00 (0.00–0.00)c 0.80 (0.00–1.04)c 0.00 (0.00–0.00)d
 7 0.00 (0.00–0.00)c 0.95 (0.69–1.05)c 0.00 (0.00–0.00)d
 10 0.00 (0.00–0.00)c 1.06 (0.98–1.17)c 0.16 (0.00–0.98)d
Experiment 2 - treatments administered 14 h prior to induction of arthritis
 1.5 0.28 (0.00–0.66)a 0.75 (0.00–0.97) 0.61 (0.00–1.02)b
 3 0.00 (0.00–0.00) 0.36 (0.00–0.84) 0.00 (0.00–0.65)
 5 0.00d (0.00–0.00)d 0.45 (0.00–0.99)d 0.00 (0.00–0.00)e
 7 0.00 (0.00–0.00)c 0.80 (0.00–1.07)c 0.00 (0.00–0.00)d
 10 0.35 (0.00–0.87)f 0.91 (0.66–1.05)f 0.00 (0.00–0.00)g
  1. Different superscripts in the same row indicate statistically significant differences: a,b p = 0.026; c,d p < 0.001; e,d p = 0.033; f,g p ≤ 0.006